Galvani Bioelectronics
Owners:
GlaxoSmithKline (GSK, GSK, GlaxoSmithKline) - 55%
Alphabet - 45%
Owners
At the end of July, 2016 it was announced that Alphabet (Google parent company) creates joint venture with pharmaceutical company GlaxoSmithKline. The new enterprise received the name Galvani Bioelectronics — in honor of the Italian scientific 18th century of Luigi Galvani, one of founders of electrophysiology. Verily Life Sciences (one of divisions of Alphabet) will receive 45% of shares of the company, GlaxoSmithKline will have remained 55%.
According to plans of founders, within the next seven years about $715 million will be invested in Galvani Bioelectronics. The company is going to concentrate the efforts on "a research, development and commercialization" of bioelectronics — rather new direction in medicine in which treatment is made by means of implantation of the devices influencing impulses of nervous cages.
The GlaxoSmithKline company considers that developments of Galvani Bioelectronics will be able to treat arthritis, asthma and type 2 diabetes. In turn, Verily Life Sciences intends to create the software and the equipment for joint venture.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |